Background/Objectives: The increasing population of childhood cancer survivors presents new challenges for healthcare systems worldwide. While advances in oncological treatments have dramatically improved survival rates, survivors face a broad spectrum of late effects that extend beyond the biological to encompass profound psychological and social dimensions. Methods: This quasi-systematic review synthesizes data from recent studies on adolescent survivors, revealing significant disruptions in cognitive function, mental health, social integration, education, romantic relationships, and vocational outcomes. Results: This review highlights the inadequacy of a solely biomedical model and advocates for a biopsychosocial approach to long-term follow-up care. An emphasis is placed on the necessity of personalized, interdisciplinary, and developmentally informed interventions, especially in countries like Poland, where structured survivorship care models remain underdeveloped. Conclusions: The findings underscore the importance of integrating medical, psychological, and social services to ensure adolescent cancer survivors achieve not only physical recovery but also meaningful life participation and emotional well-being.

Introduction: Intensive chemotherapy protocols and hematopoietic stem cell transplantation (HSCT) in children with cancer frequently lead to severe complications, such as mucositis and immune dysfunction. A growing body of evidence indicates that these complications are closely associated with the patient’s nutritional status and the composition of the gut microbiome, which becomes profoundly destabilized as a result of cytotoxic therapy and antibiotic use. Background: The aim of this review is to critically evaluate the current state of knowledge on the interplay between gut dysbiosis, metabolomic profiles—with particular emphasis on short-chain fatty acids (SCFAs)—and treatment-related toxicity in pediatric patients, as well as to delineate pathways toward personalized nutritional therapy. Methods: A narrative review was conducted, including clinical and preclinical studies published between January 2015 and October 2025. PubMed/MEDLINE, Embase, Cochrane Library, and other databases were searched, focusing on changes in microbiome composition, correlations between gut-derived metabolites and the severity of complications (sepsis, graft-versus-host disease [GvHD], mucositis), and the effects of targeted nutritional interventions (probiotics, prebiotics, postbiotics, and fecal microbiota transplantation [FMT]) on microbiome modulation during anticancer therapy. Results: The analysis demonstrates that pediatric oncologic treatment leads to a marked reduction in microbial diversity, including the loss of protective Clostridiales taxa (e.g., Faecalibacterium), accompanied by an overgrowth of Proteobacteria pathobionts. Metabolomic profiling indicates that low SCFA levels (e.g., butyrate < 20–50 µmol/g) are a strong predictor of severe mucositis, prolonged neutropenia, and an increased risk of sepsis. Interventions aimed at restoring eubiosis and enhancing SCFA production show potential in strengthening the intestinal barrier, modulating immune responses, and enabling maintenance of the planned relative dose intensity (RDI) of chemotherapy by reducing treatment-related toxicity. Conclusions: Gut microbiome profiling and fecal metabolomics represent promising prognostic tools in pediatric oncology. There is an urgent need for further research employing “omics”-based approaches to develop precise, individually tailored nutritional protocols. Such strategies, including postbiotics and FMT, may minimize treatment-related adverse effects and improve long-term clinical outcomes in pediatric patients.

Fungal infections constitute a significant challenge and continue to be a predominant cause of treatment failure in pediatric leukemia cases. Despite the implementation of antifungal prophylaxis, these infections contribute to approximately 20% of cases in children undergoing treatment for acute lymphoblastic leukemia (ALL). The aim of this study is to highlight the diagnostic and therapeutic challenges associated with invasive fungal infections (IFIs). We also present a review of the epidemiology, risk factors, treatment, and a clinical presentation of IFI in patients with ALL. This case report details the clinical course of confirmed Candida albicans (C. albicans) and Aspergillus spp. infections during the consolidation phase of ALL treatment in a 5-year-old pediatric patient. This male patient did not experience any complications until Day 28 of protocol II. Then, the patient’s condition deteriorated. Blood culture detected the growth of C. albicans. Despite the implementation of targeted therapy, the boy’s condition did not show improvement. The appearance of respiratory symptoms necessitated a computed tomography (CT) of the chest, which revealed multiple nodular densities atypical for C. albicans etiology. In spite of ongoing antifungal treatment, the lesions depicted in the CT scans showed no regression. A lung biopsy ultimately identified Aspergillus species as the source of the infection. Overcoming fungal infections poses a considerable challenge; therefore, an accurate diagnosis and the prompt initiation of targeted therapy are crucial in managing these infections in patients with leukemia.

Background. Rett syndrome (RTT) is a rare, genetic neurological disease caused by a mutation of the methyl-CpG-binding protein 2 (MECP2) gene that mainly affects girls. There is no currently available causative treatment for this disease; trofinetide is the only drug dedicated to alleviating symptoms. Aim. The aim is to present potential medicines in clinical trials that have been observed to have a therapeutic benefit in the treatment of Rett syndrome. The article contains also descriptions of pathophysiology and symptoms of Rett syndrome, which can be affected by undermentioned pharmaceuticals. Material and methods. The study used Google Scholar, PubMed, and Scopus databases as its data sources. Other information was obtained from the Clinicaltrials.gov registry and database, and reports of companies conducting drug research. The literature was filtered by keywords: ‘Rett syndrome‘, ‘clinical trials’ and ‘gene therapies‘. Results. The treatment of Rett syndrome focuses on alleviating symptoms and improving the quality of life. Trofinetide is the only substance approved by the US Food and Drug Administration (FDA), which helps to reduce behavioral problems and improve social functioning. Currently, research is underway on genetic therapies, including gene replacement therapy, which may provide more effective treatment options in the future. Additionally, research is being conducted on other drugs that reduce symptoms in patients with RTT. Conclusions. Great hopes are associated with research on gene therapies, which are currently in clinical trial phases. In the future, this could bring significant benefits to patients; their implementation may not only improve aspects of the disease, such as respiratory issues, but also can result in better survival outcomes.

Background: Contemporary pediatric oncology confronts medical staff with challenges that are not only clinical but also ethical and existential in nature. The aim of this study was to identify the cognitive and affective factors associated with medical professionals’ attitudes toward fertility preservation procedures (oncofertility) in pediatric patients. In particular, the association of “existential vacuum” (lack of life goals, sense of meaninglessness), value systems, and religiosity on the level of competence and emotional acceptance of these procedures was examined. Methods: A cross-sectional observational study was conducted between January and September 2024 in pediatric oncology centers in Poland (Gdańsk, Lublin, Łódź, and Poznań). The study group consisted of 62 medical professionals (62.9% physicians and 37.1% nurses) selected using purposive sampling. The research protocol included an Author-Designed Questionnaire, the Scheler Value Scale (SVS), the Life Attitude Profile—Revised (LAP-R), and the Centrality of Religiosity Scale (CRS-15). Statistical analyses comprised Pearson’s r correlations, multiple regression analysis, and cluster analysis using the k-means method. Results: Participants demonstrated a moderate level of substantive competence in oncofertility (M = 2.31 on a 5-point scale). Regression analysis revealed that “existential vacuum” was the strongest negative predictor of competence (B = −0.34; p = 0.001), which was found to be a significant negative correlate of professional development in this area. In the affective domain, a pronounced normative conflict was observed: religiosity was negatively correlated with emotional acceptance of the procedures (r = −0.42; p < 0.001), indicating tension between medical imperatives and worldview-based beliefs. At the same time, the regression model showed that internalized religiosity and moral values might theoretically function as an “axiological buffer”; however, due to the severe psychometric limitations of the emotional acceptance measure (α = 0.268), these affective associations are highly tentative and unstable. Alternative measurement strategies are required to validate this hypothesis. Exploratory cluster analysis suggested the potential existence of two professional profiles: “Axiologically Integrated” staff members and a larger group of “Existential Skeptics”, who exhibited higher “existential vacuum” and lower psychosocial resources. Conclusions: Viewed through a dual-process interpretative lens, a theoretical phenomenon of cognitive–affective dissociation was explored. The highly tentative data suggest that “existential vacuum” might represent a hypothesized barrier to competence acquisition. Furthermore, findings regarding the affective domain—limited by the low reliability of the emotional measure—suggest religiosity could act as a potential source of normative tension. These exploratory profiles serve as hypotheses for future intervention designs rather than definitive clinical mechanisms.